```json
{
"content": [
{
"type": "paragraph",
"content": "Over the past year the Portable Non-Mydriatic Fundus Camera market has gained speed through strategic partnerships, M&A activity, and new product rollouts. XYZ Medical teamed with AI startup ClearSight to embed real‑time analysis, while MedScope’s acquisition of RetinaTech expanded European distribution. Launches such as the ultra‑light CamX‑Pro and cloud‑linked OmniEye 2024 lifted resolution and data security. In June 2024 the FDA granted Class II clearance for handheld devices with autonomous screening, accelerating tele‑ophthalmology adoption. Venture capital reached $120 million in Q3 2024, supporting Southeast Asian manufacturing expansion. These moves illustrate the Portable Non-Mydriatic Fundus Camera industry trends shaping market growth."
},
{
"type": "list",
"items": [
{ "text": "Enterprise eye‑care networks are installing portable cameras in primary‑care offices, enabling on‑site diabetic‑retinopathy screening and reducing referral delays.", "level": 1 },
{ "text": "Consumer tele‑health services reported a 35 % increase in demand for at‑home retinal imaging kits, driven by awareness of vision health post‑pandemic.", "level": 1 },
{ "text": "The EU’s revised MDR 2023 re‑classifies handheld fundus devices as high‑risk, prompting manufacturers to adopt enhanced cybersecurity and post‑market surveillance measures.", "level": 1 },
{ "text": "Visionary Health’s $45 million
